Insulins

Peptide hormones that cause an increase in the absorption of GLUCOSE by cells within organs such as LIVER; MUSCLE and ADIPOSE TISSUE. During normal metabolism insulins are produced by the PANCREATIC BETA CELLS in response to increased GLUCOSE. Natural and chemically-modified forms of insulin are also used in the treatment of GLUCOSE METABOLISM DISORDERS such as DIABETES MELLITUS.

Networked: 644 relevant articles (44 outcomes, 96 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bolli, Geremia B: 9 articles (10/2020 - 11/2004)
2.	Rosenstock, Julio: 7 articles (01/2022 - 04/2012)
3.	Riddle, Matthew C: 6 articles (01/2018 - 02/2004)
4.	Heise, Tim: 5 articles (01/2022 - 01/2014)
5.	Mathieu, Chantal: 5 articles (12/2021 - 12/2012)
6.	Kalra, Sanjay: 5 articles (02/2021 - 01/2016)
7.	Home, Philip D: 5 articles (01/2018 - 01/2012)
8.	Hompesch, Marcus: 4 articles (01/2022 - 03/2011)
9.	Sherr, Jennifer L: 4 articles (01/2022 - 11/2011)
10.	Giugliano, Dario: 4 articles (08/2021 - 12/2012)

Related Diseases

1.	Hypoglycemia (Reactive Hypoglycemia) 08/01/2022 - "In addition, most intensification studies also revealed a significantly lower risk of nocturnal hypoglycemia with Gla-100-based regimens versus NPH and premixed insulins and a significantly greater risk compared to second-generation basal insulins. " 11/01/2021 - "All basal insulins are similar in efficacy, with only small differences among them in terms of the risk of hypoglycemia. " 05/01/2019 - "Second-generation insulins have comparable efficacy, with some differences in the risk of hypoglycemia." 08/01/2022 - "In these studies, overall hypoglycemia risk with Gla-100 was significantly lower compared with IDet and comparable to NPH, premixed insulins, co-formulations, and second-generation basal insulins. " 05/01/2019 - "A single study showed similar metabolic control with subtle differences in the risk of hypoglycemia among second generation insulins. "
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2007 - "In addition, strategies where efficacy of the available analogue insulins can be maximally utilised in both type 1 and type 2 diabetes mellitus are described. " 11/01/2021 - "The current study suggested that IDeg and Gla300 have similar effects in reducing HbA1c and gaining BMI after switching from other basal insulins in Japanese patients with type 1 diabetes and type 2 diabetes. " 03/01/2021 - "A Pragmatic Study of Basal and Mid-Mixture Insulins as Starter Insulins in Chinese Patients With Type 2 Diabetes: Observations From Long-Term, Real-World Experience." 01/01/2021 - "This review aims to describe its advantages compared to some other rapid insulins thanks to data obtained from trials in type 1 and type 2 diabetes. " 10/30/2020 - "Using 2nd generation basal insulins in type 2 diabetes: Costs and savings in a comparative economic analysis in Italy, based on the BRIGHT study."
3.	Weight Gain 02/01/2011 - "Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes." 10/01/2021 - "Randomized controlled trials (RCTs) with ≥ 12 weeks of follow-up comparing efficacy (HbA1c) or safety (hypoglycemia and weight gain) between second-generation basal insulins vs. other basal insulins in T1D adults were included. " 01/01/2022 - "INI is safe in older people with diabetes treated with systemic insulins, and it is not associated with adverse events, hypoglycemia or weight gain. " 05/01/2019 - "Hypoglycemia or weight gain can be minimized with proper titration and use of second-generation basal insulins. " 01/01/2007 - "Pharmacokinetic limitations of conventional insulins have been a barrier to achieving treatment targets secondary to adverse effects such as hypoglycemia and weight gain. "
4.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 05/01/2010 - "MEDLINE and congress proceedings were searched for randomized controlled trials comparing prandial insulins in a basal-bolus regimen in adults or children/adolescents with type 1 diabetes. " 06/01/2023 - "[New Insulins for Type 1 Diabetes treatment]." 01/01/2023 - "In Type 1 diabetes patients, even ultra-rapid acting insulins injected subcutaneously reach peak concentrations in 45 minutes or longer. " 06/01/2022 - "Treatment combining long-acting and short-acting insulins is essential for people with type 1 diabetes, but may become also compulsory in other forms of diabetes in case of insulinopenia. " 01/01/2022 - "In a single-centre, randomized, double-blinded phase 1 crossover study, we used the manual euglycaemic clamp technique to compare PK and PD profiles between single subcutaneous doses (0.3 units/kg) of the two regular insulins in participants with type 1 diabetes (T1DM) with a washout period of 14 (± 7) days between tests. "
5.	Diabetes Mellitus 01/01/2022 - "Basal insulins are safe and effective in patients with CKD and diabetes mellitus but we do not have specific studies. " 02/01/2017 - "Objetive: This study evaluated the results of treatment adherence scales in two cohorts of patients with diabetes mellitus treated either with human or analogue insulins. " 11/01/1974 - "Comparative trials with monocomponent (MC) and monospecies (MS) pork insulins in the treatment of diabetes mellitus. " 01/01/2023 - "The advent of newer diabetes mellitus technologies and newer insulins herald improvements in management strategies and hypoglycaemia prevention. " 07/01/2022 - "For the treatment of diabetes mellitus (DM) in dogs, novel insulins with decreased injection frequency while maintaining safety and efficacy are desirable. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Insulin Glargine (Lantus)
3.	Insulin Lispro (Humalog)
4.	insulin degludec
5.	Hypoglycemic Agents (Hypoglycemics)
6.	Insulin Detemir (Levemir)
7.	Glucose (Dextrose)
8.	Protamines (Protamine Sulfate)
9.	Short-Acting Insulin
10.	Blood Glucose (Blood Sugar)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Injections
4.	Drug Therapy (Chemotherapy)
5.	Subcutaneous Injections